Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 3/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214438 | 0.84 | HCRTR2 (0.57) | HCRTR2FFAR4GAAKDM4EL3MBTL1 | |
| SCHEMBL31214415 | 0.78 | L3MBTL1 (0.42) | ALDH1A1SMN1; SMN2GAAKDM4EHTT | |
| SCHEMBL31214342 | 0.74 | NOS2 (0.36) | HCRTR2FFAR4 | |
| SCHEMBL2130737 | 0.74 | GAA (0.39) | ALDH1A1SMN1; SMN2GAAKDM4EHTT | |
| SCHEMBL31214396 | 0.73 | HCRTR2 (0.32) | HCRTR2ALDH1A1CCR5SMN1; SMN2 | |
| SCHEMBL353204 | 0.70 | KDM4E (0.40) | ALDH1A1CCR5SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL31214440 | 0.70 | NOS2 (0.35) | HCRTR2 | |
| SCHEMBL7612137 | 0.69 | L3MBTL1 (0.38) | ALDH1A1CCR5SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL9504653 | 0.69 | KDM4E (0.39) | ALDH1A1CCR5SMN1; SMN2KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL4249059 | 0.69 | KDM4E (0.39) | ALDH1A1CCR5SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| WO-2024211744-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | HCRTR2 113/4885FFAR4 1940/4885ALDH1A1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.